Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial

MLA

Dorothy Cheung, et al. “Astegolimab (Anti-ST2) Efficacy and Safety in Adults with Severe Asthma: A Randomized Clinical Trial.” The Journal of Allergy and Clinical Immunology, vol. 148, no. 3, Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....fdb6a51aa3047a982bc801f6903e7bec&authtype=sso&custid=ns315887.

APA

Dorothy Cheung, Weily Soong, Steven G. Kelsen, Xiaoying Yang, Rajita Pappu, David F. Choy, Elliot Israel, Geoffrey Chupp, Christopher E. Brightling, Tracy Staton, Alice Fong, Michael J. Dolton, Ajit Dash, Ioana Agache, & Wiebke Theess. (2021). Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. The Journal of Allergy and Clinical Immunology, 148(3).

Chicago

Dorothy Cheung, Weily Soong, Steven G. Kelsen, Xiaoying Yang, Rajita Pappu, David F. Choy, Elliot Israel, et al. 2021. “Astegolimab (Anti-ST2) Efficacy and Safety in Adults with Severe Asthma: A Randomized Clinical Trial.” The Journal of Allergy and Clinical Immunology 148 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....fdb6a51aa3047a982bc801f6903e7bec&authtype=sso&custid=ns315887.